{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T04:42:53Z","timestamp":1781498573032,"version":"3.54.1"},"reference-count":45,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>The purpose of the article<\/jats:title><jats:p>In recent years, a renewed interest has emerged in investigating the use of MDMA in the treatment of mental disorders. However, knowledge about the characteristics of recreational use of MDMA, its contexts and effects are limited.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>We recruited adult Norwegian participants aged 18 to 65 who reported having had a memorable experience after using MDMA. They completed an anonymous internet survey with 150 items covering matters related to recreational use of MDMA, as well as four standardized measures related to their experience and to personality functioning. We present descriptive statistics (frequencies, means, and standard deviations) from the survey.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>We recruited 654 participants, 608 of which were eligible for inclusion in the data analysis (60.5% male; 89% 45 years or younger). Participants reported recreational (65.5%) and therapeutic (22.9%) motivation for MDMA use, mostly at home (28.3%) or at somebody else\u2019s home (34.4%). Participants were well prepared (63%) and most had a clear intention behind their use (54.3%). They were clearly in favor of using MDMA therapeutically (84.7%). Mental distress or disorders were frequently reported (82.1%), but also a large degree of improvement, especially for internalizing disorders such as PTSD, social anxiety and depression. Persistent negative effects were relatively rare and short lived.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Our sample reported positive experiences and effects of recreational MDMA use, with a small minority reporting problematic effects and negative experiences. Self-perceived symptoms were reported as improved, especially for internalizing disorders. Participants reported positive changes in many aspects of life.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2025.1619676","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T05:31:39Z","timestamp":1758864699000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Recreational MDMA use in Norway: results from an internet convenience sample"],"prefix":"10.3389","volume":"16","author":[{"given":"Cato","family":"Gr\u00f8nner\u00f8d","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thea","family":"R\u00f8nningen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid Rike","family":"Haugsj\u00e5","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristoffer A. A.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Lindvall Dahlgren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tor-Morten","family":"Kvam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1097\/ADM.0000000000001188","article-title":"Prevalence and correlates of past year ecstasy\/MDMA use in the United States","volume":"17","author":"Yang","year":"2023","journal-title":"J Addict Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"3434","DOI":"10.1038\/s41598-024-51355-6","article-title":"Subjective long-term emotional and social effects of recreational MDMA use: The role of setting and intentions","volume":"14","author":"Elmer","year":"2024","journal-title":"Sci Rep"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1080\/09687637.2016.1243091","article-title":"Continued signs of resilience in the European drug market: Highlights from the EMCDDA\u2019s 2016 European drug report","volume":"23","author":"Mounteney","year":"2016","journal-title":"Drugs: Education Prev Policy"},{"key":"B4","article-title":"Narkotikabruk i Norge","author":"Sand\u00f8y","year":"2024"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02791072.2025.2452226","article-title":"Down the rabbit hole: A large-scale survey of psychedelic users\u2019 Patterns of use and perceived effects","author":"Cuttler","year":"2025","journal-title":"J Psychoactive Drugs"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugpo.2024.104507","article-title":"The Global Psychedelic Survey: Consumer characteristics, patterns of use, and access in primarily anglophone regions around the world","volume":"130","author":"Lake","year":"2024","journal-title":"Int J Drug Policy"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s12144-024-07017-x","article-title":"Pattern of psychedelic substance use: A comparison between populations in Spain and South America using the Psychedelic Use Scale (PUS)","volume":"43","author":"Rojas-Hern\u00e1ndez","year":"2024","journal-title":"Curr Psychol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s12954-024-00979-y","article-title":"Harm reduction behaviours and harm experiences of people who use 3,4-methylenedioxymethamphetamine (MDMA) in Aotearoa New Zealand","volume":"21","author":"Whelan","year":"2024","journal-title":"Harm Reduction J"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1176\/appi.focus.23021011","article-title":"MDMA-assisted therapy for severe PTSD: A randomized, double-blind, placebo-controlled phase 3 study","volume":"21","author":"Mitchell","year":"2023","journal-title":"Focus"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02565-4","article-title":"MDMA-assisted therapy for moderate to severe PTSD: A randomized, placebo-controlled phase 3 trial","volume":"29","author":"Mitchell","year":"2023","journal-title":"Nat Med"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.1995","article-title":"MDMA-assisted psychotherapy for treatment of posttraumatic stress disorder: A systematic review with meta-analysis","volume":"62","author":"Smith","year":"2022","journal-title":"J Clin Pharmacol"},{"key":"B12","article-title":"Breakthrough Therapy","year":"2018"},{"key":"B13","doi-asserted-by":"publisher","first-page":"83","DOI":"10.2147\/SAR.S37258","article-title":"3,4-methylenedioxymethamphetamine (MDMA): current perspectives","volume":"4","author":"Meyer","year":"2013","journal-title":"Subst Abuse Rehabil"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.565","article-title":"Potential psychiatric uses for MDMA","volume":"101","author":"Yazar-Klosinski","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1002\/hup.2318","article-title":"Human psychobiology of MDMA or \u2018Ecstasy\u2019: An overview of 25 years of empirical research","volume":"28","author":"Parrott","year":"2013","journal-title":"Hum Psychopharmacology: Clin Exp"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1177\/2050324516683325","article-title":"Constructing drug effects: A history of set and setting","volume":"3","author":"Hartogsohn","year":"2017","journal-title":"Drug Science Policy Law"},{"key":"B17","volume-title":"A Manual for MDMA-Assisted Psychotherapy in the Treatment of Posttraumatic Stress Disorder","author":"Mithoefer","year":"2013"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s11013-021-09764-z","article-title":"Evenings with molly: adult couples\u2019 Use of MDMA for relationship enhancement","volume":"47","author":"Colbert","year":"2023","journal-title":"Culture Medicine Psychiatry"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopsych.2010.08.003","article-title":"Is ecstasy an \u201cEmpathogen\u201d? Effects of \u00b13,4-methylenedioxymethamphetamine on prosocial feelings and identification of emotional states in others","volume":"68","author":"Bedi","year":"2010","journal-title":"Biol Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1177\/02698811211055809","article-title":"Debunking the myth of \u2018Blue Mondays\u2019: No evidence of affect drop after taking clinical MDMA","volume":"36","author":"Sessa","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1177\/02698811221100713","article-title":"Not too quick on \u201cDebunking the myth of \u2018Blue Mondays\u2019","volume":"36","author":"Flameling","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1007\/s002130000648","article-title":"Gender differences in the subjective effects of MDMA","volume":"154","author":"Liechti","year":"2001","journal-title":"Psychopharmacology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1007\/s002130050714","article-title":"Ecstasy (MDMA) effects upon mood and cognition: Before, during and after a Saturday night dance","volume":"139","author":"Parrott","year":"1998","journal-title":"Psychopharmacology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117691569","article-title":"Safety pharmacology of acute MDMA administration in healthy subjects","volume":"31","author":"Vizeli","year":"2017","journal-title":"J Psychopharmacol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.drugpo.2017.07.030","article-title":"From ecstasy to MDMA: Recreational drug use, symbolic boundaries, and drug trends","volume":"50","author":"Edland-Gryt","year":"2017","journal-title":"Int J Drug Policy"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1177\/02698811251346729","article-title":"Naturalistic use of psychedelics is associated with longitudinal improvements in anxiety and depression during global crisis times","volume":"39","author":"B\u0103l\u0103e\u0163","year":"2025","journal-title":"J Psychopharmacol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2025.152598","article-title":"Changes in recreational drug use, reasons for those changes and their consequence during and after the COVID-19 pandemic in the UK. Comprehensive","volume":"140","author":"B\u0103l\u0103e\u0163","year":"2025","journal-title":"Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1287196","article-title":"Epidemiology of classic psychedelic substances: Results from a Norwegian internet convenience sample","volume":"14","author":"Kvam","year":"2023","journal-title":"Front Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1177\/02698811211066709","article-title":"Validation of the Psychological Insight Scale: A new scale to assess psychological insight following a psychedelic experience","volume":"36","author":"Peill","year":"2022","journal-title":"J Psychopharmacol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/0269881119855974","article-title":"Emotional breakthrough and psychedelics: Validation of the Emotional Breakthrough Inventory","volume":"33","author":"Roseman","year":"2019","journal-title":"J Psychopharmacol"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1177\/0269881116678781","article-title":"The Challenging Experience Questionnaire: Characterization of challenging experiences with psilocybin mushrooms","volume":"30","author":"Barrett","year":"2016","journal-title":"J Psychopharmacol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/pmh.1434","article-title":"The Level of Personality Functioning Scale-Brief Form 2.0: Update of a brief instrument for assessing level of personality functioning","volume":"13","author":"Weekers","year":"2019","journal-title":"Pers Ment Health"},{"key":"B33","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.jpsychires.2025.05.062","article-title":"Adverse reactions among psychedelic users: Norwegian validation of the Challenging Experience Questionnaire","volume":"189","author":"Andersen","year":"2025","journal-title":"J Psychiatr Res"},{"key":"B34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1080\/00223891.2023.2182694","article-title":"Evaluating the construct validity of the norwegian version of the level of personality functioning scale \u2013 brief form 2.0 in a large clinical sample","volume":"106","author":"Paap","year":"2024","journal-title":"J Pers Assess"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1037\/pas0000450","article-title":"Development and initial evaluation of a self-report form of the DSM\u20135 Level of Personality Functioning Scale","volume":"29","author":"Morey","year":"2017","journal-title":"psychol Assess"},{"key":"B36","article-title":"Earnings statistics","year":"2025"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2023.1184681","article-title":"Associations between the use of psychedelics and other recreational drugs with mental health and resilience during the COVID-19 pandemic","volume":"14","author":"B\u0103l\u0103e\u021b","year":"2023","journal-title":"Front Psychiatry"},{"key":"B38","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1176\/appi.ajp.20230681","article-title":"MDMA and MDMA-assisted therapy","volume":"182","author":"Wolfgang","year":"2025","journal-title":"Am J Psychiatry"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1177\/0269881118754710","article-title":"Psychedelics and the essential importance of context","volume":"32","author":"Carhart-Harris","year":"2018","journal-title":"J Psychopharmacol"},{"key":"B40","unstructured":"R\u00f8nningen\n              T\n            \n            \n              Haugsj\u00e5\n              IR\n            \n          \n          Oslo, Norway\n          University of Oslo\n          Opplevd endring av depresjonstilstand etter en minneverdig opplevelse med MDMA [Perceived change in depression after a memorable MDMA experience]\n          \n          2025"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1016\/j.nsa.2024.104179","article-title":"Exploration of MDMA-assisted therapy for major depressive disorder: A proof of principle study","volume":"3","author":"Kvam","year":"2024","journal-title":"Neurosci Appl"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1016\/j.neubiorev.2024.105570","article-title":"Who are you after psychedelics? A systematic review and a meta-analysis of the magnitude of long-term effects of serotonergic psychedelics on cognition\/creativity, emotional processing and personality","volume":"158","author":"Solaja","year":"2024","journal-title":"Neurosci Biobehav Rev"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2005.08.005","article-title":"Party people: Personality and MDMA use of house party visitors","volume":"31","author":"ter Bogt","year":"2006","journal-title":"Addictive Behav"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1177\/0269881117711712","article-title":"Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted psychotherapy","volume":"31","author":"Wagner","year":"2017","journal-title":"J Psychopharmacol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1176\/appi.focus.20220056","article-title":"MDMA-assisted psychotherapy for borderline personality disorder","volume":"20","author":"Traynor","year":"2022","journal-title":"Focus"}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1619676\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T05:31:41Z","timestamp":1758864701000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2025.1619676\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":45,"alternative-id":["10.3389\/fpsyt.2025.1619676"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2025.1619676","relation":{},"ISSN":["1664-0640"],"issn-type":[{"value":"1664-0640","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]},"article-number":"1619676"}}